Haemophilus influenzae Vaccines

Creative Biolabs is a world leader in the field of bacterial vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against disease caused by Haemophilus influenzae and guarantee the finest results for our customers all over the world.

Haemophilus influenzae Vaccines - Creative Biolabs

Haemophilus influenzae (H. influenzae) is a small pleomorphic, gram-negative coccobacillus belonging to the Pasteurellaceae family which was isolated primarily from the human respiratory tract. H. influenzae has two major categories which are the unencapsulated strains and the encapsulated strains. The unencapsulated strains are termed nontypable (NTHi) because they lack capsular serotypes. Encapsulated strains possess six serotypes (a-f) based on capsular polysaccharide and the most virulent strain is type b (Hib). Hib strains cause invasive diseases which include pneumonia, severe swelling in the throat, making it hard to breathe, infections of the blood, joints, bones, covering of the heart and death. H. influenzae is transmitted person-to-person and some illnesses like bloodstream infections are very serious. The vaccines against H. influenzae are mainly based on Hib.

Combination Vaccines

Two combination vaccines are made when two or more types of vaccine are combined together into a single shot, so that one vaccination can protect against more than one disease. One of the vaccines is the Hib/MenC vaccine. It is a single injection given to 1-year-old babies to boost their protection against Hib and meningitis C. They can both cause meningitis and septicaemia. Another is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Hib which is approved for use as a four-dose series in children with the age prior to 5th birthday.

Conjugate Hib Vaccines

There are several Hib vaccines which conjugate the protein carriers to a piece of the polysaccharide capsule from a Hib bacterium to create an effective protection. One vaccine is consists of the Hib capsular polysaccharide (polyribosylribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the Hib strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid. Potency of this vaccine is specified on each lot by limits on the content of PRP polysaccharide and protein in each dose and the proportion of polysaccharide and protein in the vaccine that is characterized as high molecular weight conjugate. Another vaccine contains PRP which was prepared from the Hib strain 20,752 grown in a synthetic medium that undergoes heat inactivation and purification. In addition, there is a highly purified capsular polysaccharide (polyribosylribitol phosphate or PRP) of Hib that is covalently bound to an outer membrane protein complex (OMPC) of the B11 strain of Neisseria meningitidis serogroup B. These vaccines use different carrier proteins and all of the vaccines are highly effective against Hib bacteria for people who receive a complete primary series.

Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of bacterial vaccine development. We have experts who are able to help you with the vaccine development against disease caused by Haemophilus influenzae. If you are interested in our services, please contact us for more details.

Our services are for research use only. We do not provide services directly to individuals.

Online Inquiry

*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.


45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-466-5530
Fax: 1-631-207-8356
UK - Germany

Follow us on

facebook   twitter   linked   blog

Shopping Basket